1.24  -0.06 (-4.62%)		03-20 16:00
Open: 1.315 High: 1.37 Volume: 184,534		Pre. Close: 1.3 Low: 1.1608 Market Cap: 33(M)

Short term
Mid term
Targets	6-month :	1.53	1-year :	1.69
Resists	First :	1.31	Second :	1.45
Pivot price	1.25
Supports	First :	1.08	Second :	0.89
MAs	MA(5) :	1.33	MA(20) :	1.24
	MA(100) :	1.31	MA(250) :	1.43
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	51.8	D(3) :	68.6
RSI	RSI(14): 48.6
52-week	High :	2.4	Low :	1.01

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RNTX ] has closed above bottom band by 43.6%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.37 - 1.38	1.38 - 1.39
Low:	1.14 - 1.15	1.15 - 1.16
Close:	1.23 - 1.24	1.24 - 1.25

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Tue, 03 Mar 2026
Experimental inhaled IPF drug resumes Phase 2 testing after FDA clearance - Stock Titan

Tue, 03 Mar 2026
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis - The Manila Times

Mon, 02 Mar 2026
[8-K] Rein Therapeutics, Inc. Reports Material Event | RNTX SEC Filing - Form 8-K - Stock Titan

Mon, 02 Mar 2026
Rein Therapeutics Raises $2.3 Million in Private Unsecured Notes With 20% OID, Due by Jun 30, 2026 - TradingView

Thu, 19 Feb 2026
Rein Therapeutics Announces Immediate Board Director Resignation - TipRanks

Thu, 11 Dec 2025
Rein Therapeutics ends agreements with Yorkville, incurs no penalties - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	26 (M)
Shares Float	20 (M)
Held by Insiders	0 (%)
Held by Institutions	41.1 (%)
Shares Short	437 (K)
Shares Short P.Month	351 (K)

EPS	-2.95
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.05
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-18.9 %
Return on Equity (ttm)	-83.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.91
Qtrly Earnings Growth	0 %
Operating Cash Flow	-21 (M)
Levered Free Cash Flow	-13 (M)

PE Ratio	-0.43
PEG Ratio	0
Price to Book value	24.79
Price to Sales	0
Price to Cash Flow	-1.56

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.